Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study

Alex F. Herrera, Jasmine Zain, Kerry J. Savage, Tatyana Feldman, Jonathan E. Brammer, Lu Chen, Sandrine Puverel, Leslie Popplewell, Lihua E. Budde, Matthew Mei, Chitra Hosing, Ranjit Nair, Lori A. Leslie, Shari Daniels, Lacolle Peters, Stephen J. Forman, Steven T. Rosen, Larry W. Kwak, Swaminathan P. Iyer